1997 Annual Report
Product Review Financials Setting
  | Financial Highlights | Financial Review |
| Management’s Report | Audit Committee’s Report |
| Independent Auditors’ Report | Financial Statements
| Notes to Financial Statements |
| Directors, Committees, and Officers |
| Corporate and Shareholder Information |
| Consolidated Income |
| Consolidated Balance Sheet |
| Consolidated Shareholder’s Equity|
| Consolidated Cash Flows |
| Segment Information | Geographic Data |
| Quarterly Data | Financial Summary |
 

  Consolidated Statement of Shareholders’ Equity
  Pfizer Inc and Subsidiary Companies

  Common stock
        Treasury stock
 
 (millions) Shares Par Value Additional Paid-In Capital Retained Earnings Currency Translation Adjustment and Other Employee Benefit Trust Shares Cost



Total
  • Balance January 1,1995, as reported
  • 681 $34 $651  $5,945  $196  $ (749) (52) $(1,753) $4,324 
  • Restatement for the 1997 stock split
  • 680 35 (35) —  —  —  (52) —  — 
  • Balance January 1, 1995 as restated
  • 1,361 69 616  5,945  196  (749) (104) (1,753) 4,324 
  • Net income
  •       1,573          1,573 
  • Cash dividends declared
  •       (659)         (659)
  • Currency translation adjustment
  •         12        12 
  • Stock option transactions
  • 9 126        79  205 
  • Purchases of common stock
  •             (5) (108) (108)
  • Employee benefit trust transactions — net
  •     440      (421)     19 
  • Unrealized net gain on available-for-sale securities — net
  •         23        23 
  • Minimum pension liability — net
  •         (68)       (68)
  • Treasury stock utilized for acquisition
  •             167  167 
  • Other
  • 1 18            18 
  • Balance December 31, 1995
  • 1,371 69 1,200  6,859  163  (1,170) (96) (1,615) 5,506 
  • Net income
  •       1,929          1,929 
  • Cash dividends declared
  •       (771)         (771)
  • Currency translation adjustment
  •         (32)       (32)
  • Stock option transactions
  • 7 124        10  156  280 
  • Purchases of common stock
  •             (1) (27) (27)
  • Employee benefit trust transactions — net
  •     341      (318)     23 
  • Unrealized net gain on available-for-sale securities — net
  •         15        15 
  • Other
  • 28    (1)   —  31 
  • Balance December 31, 1996
  • 1,378 69 1,693 8,017  145  (1,488) (87) (1,482) 6,954 
  • Net income
  •       2,213          2,213 
  • Cash dividends declared
  •       (881)         (881)
  • Currency translation adjustment
  •         (253)       (253)
  • Stock option transactions
  • 9   343       68  411 
  • Purchases of common stock
  •             (11) (586) (586)
  • Employee benefit trusts transactions — net
  •     1,177      (1,158) —  26 
  • Unrealized net gain on available-for-sale securities — net
  •         20        20 
  • Other
  • 1   26         29 
  • Balance December 31, 1997
  • 1,388 $69 $3,239 $9,349  $(85) $(2,646) (94) $(1,993) $7,933 
    See Notes to Consolidated Financial Statements which are an integral part of these statements.
      letter back top next
      Logo Imagemap
      intended for investors
      Advisory Information for Investors
      Copyright © 1997, 1998 Pfizer Inc All rights reserved.